Use of a column-switching high-performance liquid chromatography method to assess the presence of specific binding of (R)- and (S)-[11C]rolipram and their labeled metabolites to the phosphodiesterase-4 enzyme in rat plasma and tissues

Nuclear Medicine and Biology

Volumn 35, Issue 4, 2008, Pages 515-521

  Kenk, Miran ^a,b   Greene, Michael ^a,b   Lortie, Mireille ^a   deKemp, Robert A ^a   Beanlands, Rob S ^a,b   DaSilva, Jean N ^a,b  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

11C Labeled metabolites; HPLC; Imaging cAMP mediated signaling; PDE4; Positron emission tomography

Indexed keywords

DRUG METABOLITE; PHOSPHODIESTERASE IV; RADIOPHARMACEUTICAL AGENT; ROLIPRAM; ROLIPRAM C 11;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BRAIN; BROWN ADIPOSE TISSUE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; DRUG RETENTION; DRUG TISSUE LEVEL; HEART; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOTOPE LABELING; MALE; NONHUMAN; PANCREAS; RAT; SKELETAL MUSCLE;

ADIPOSE TISSUE, BROWN; ANIMALS; BINDING, COMPETITIVE; BRAIN; CARBON RADIOISOTOPES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; HEART; HYDROPHOBICITY; MALE; MUSCLE, SKELETAL; PANCREAS; PHOSPHODIESTERASE INHIBITORS; PLASMA; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; ROLIPRAM; STEREOISOMERISM; TISSUE DISTRIBUTION; WHOLE-BODY COUNTING;

EID: 43049161157     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2008.01.004     Document Type: Article

References (15)

1. Houslay M.D. PDE4 cAMP-specific phosphodiesterases. Prog Nucleic Acid Res Mol Biol 69 (2001) 249-315
2. Laliberte F., Liu S., Gorseth E., Bobechko B., Bartlett A., Lario P., et al. In vitro PKA phosphorylation-mediated human PDE4A4 activation. FEBS Lett 512 (2002) 205-208
3. Pyne N.J., and Furman B.L. Cyclic nucleotide phosphodiesterases in pancreatic islets. Diabetologia 46 (2003) 1179-1189
4. Torphy T.J. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 157 (1998) 351-370
5. Nagaoka T., Shirakawa T., Balon T.W., Russell J.C., and Fujita-Yamaguchi Y. Cyclic nucleotide phosphodiesterase 3 expression in vivo: evidence for tissue-specific expression of phosphodiesterase 3A or 3B mRNA and activity in the aorta and adipose tissue of atherosclerosis-prone insulin-resistant rats. Diabetes 47 (1998) 1135-1144
6. Wachtel H. The second-messenger dysbalance hypothesis of affective disorders. Pharmacopsychiatry 23 (1990) 27-32
7. Takahashi K., Osanai T., Nakano T., Wakui M., and Okumura K. Enhanced activities and gene expression of phosphodiesterase types 3 and 4 in pressure-induced congestive heart failure. Heart Vessels 16 (2002) 249-256
8. Schneider H.H., Schmiechen R., Brezinski M., and Seidler J. Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol 127 (1986) 105-115
9. 11)C]rolipram to phosphodiesterase-4 provides the basis for studying intracellular cAMP signaling in the myocardium and other peripheral tissues. Nucl Med Biol 34 (2007) 71-77
10. 11C]rolipram for PET imaging of phosphodiesterase-4: in vivo binding, metabolism, and dosimetry studies in rats. Nucl Med Biol 28 (2001) 347-358
11. Krause W., and Kühne G. High-performance liquid chromatographic procedure for specificity testing of radioimmunoassays: rolipram. J Chromatogr 573 (1992) 303-308
12. 11C]rolipram. J Label Compd Radiopharm 44 (2001) 373-384
13. Hilton J., Yokoi F., Dannals R.F., Ravert H.T., Szabo Z., and Wong D.F. Column-switching HPLC for the analysis of plasma in PET imaging studies. Nucl Med Biol 27 (2000) 627-630
14. 11C]rolipram in rat brain, lung and heart. Life Sci 79 (2006) 356-364
15. Krause W., and Kühne G. Biotransformation of the antidepressant d,l-rolipram: II. Metabolite patterns in man, rat, rabbit, rehesus and cynomolgus monkey. Xenobiotica 23 (1993) 1277-1288